Biochemical tumor marker plays a critical role in diagnosis, monitoring, and clinical decision making. With increasing pressure on laboratories to ensure accuracy and consistency across preexamination, examination, and postexamination processes, the new CLSI C65 standard provides the guidance needed to reduce risk and improve confidence in patient results.
Practical recommendations to support accurate and reliable biochemical tumor marker testing, including:
Appropriate test selection for both diagnosed and suspected cancer cases
Proper specimen handling to protect result integrity
Method selection to ensure consistent performance
Internal and external quality control procedures
Identification of clinically relevant interferences or confounding factors
Clear and consistent post-examination reporting practices
